



**hVIVO plc**  
("hVIVO" or the "Company")

**Notice of Interim Results**

**London, UK 23 August 2019: hVIVO plc (AIM: HVO)**, an industry leading clinical development services business pioneering human disease models based upon viral challenge, will announce its interim financial results for the six months ended 30 June 2019 on Thursday 19 September 2019.

A presentation and webcast for analysts will be held at 11.00am BST at the offices of FTI Consulting, 200 Aldersgate, Aldersgate Street, London, EC1A 4HD, with registration and coffee from 10.45am. A webcast recording of the event will be available on the Company's website.

**For further information please contact:**

**hVIVO plc**

Trevor Phillips (Executive Chairman)

+44 207 756 1300

Fleur Wood (EVP, Investor Relations & Communications)

**Numis Securities Limited**

+44 207 260 1000

Freddie Barnfield / Huw Jeremy (Nominated Adviser)

James Black (Corporate Broking)

**FTI Consulting**

Simon Conway / Victoria Foster Mitchell

+44 203 727 1000

**Notes to Editors:**

hVIVO plc ("hVIVO") is pioneering a human-based clinical trial platform to accelerate drug and vaccine development in respiratory and infectious diseases. Leveraging human disease models in flu, RSV, HRV and respiratory indications, the hVIVO platform captures disease in motion, illuminating the entire disease life cycle from healthy to sick and back to health. Based in the UK, market leader hVIVO has conducted more than 50 clinical studies and inoculated over 2500 volunteers.